^
    Back
    Association details:
    Biomarker:EGFR mutation + MDM4 *32C>A
    Cancer:Lung Adenocarcinoma
    Drug:gefitinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2018
    Title:

    The functional MDM4 genetic variant in advanced lung adenocarcinoma patients treated with EGFR-TKIs

    Published date:
    10/01/2018
    Excerpt:
    384 patients with stage IIIB or IV lung adenocarcinoma were recruited between January 2009 and June 2013. Patients were treated with gefitinib orally at a daily dose of 250 mg as 1st-line monotherapy….in the EGFR mutation-positive subgroup, individuals with MDM4 rs4245739AC genotype showed 14.1 months prolonged PFS (28.8 months vs. 14.7 months; P¼ 0.022) and 12.2 months prolonged OS (31.4 months vs. 19.2 months; P¼ 0.047) compared to the AA group.
    DOI:
    https://doi.org/10.1093/annonc/mdy269.079